MicroRNA-484 is More Highly Expressed in Serum of Early Breast Cancer Patients Compared to Healthy Volunteers

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2014 Mar 20

PMID 24641801

Citations 46

Authors

Silvia Zearo

Edward Kim

Ying Zhu

Jing Ting Zhao

Stan B Sidhu

Bruce G Robinson

Patsy Sh Soon

Affiliations

Soon will be listed here.

Abstract

Background: Previous studies have profiled breast cancer compared to normal breast tissue and identified differentially expressed microRNAs (miRNAs). These miRNAs are then assessed in serum of breast cancer patients compared to healthy volunteers. MiRNAs in serum however do not always reflect what is in tissue and important serum miRNAs may be missed. PCR arrays were therefore performed on serum samples from breast cancer patients compared to healthy volunteers with the aim of identifying circulating miRNAs that are more highly expressed in serum from early breast cancer patients compared to controls.

Methods: Taqman low density array (TLDA) cards were used to profile serum miRNAs in a discovery cohort of serum from 39 early breast cancer patients compared to 10 healthy volunteers. The results were confirmed in a validation cohort of serum from 98 early breast cancer patients compared to 25 healthy volunteers using customized qPCR plates.

Results: Seventeen miRNAs were found to have significantly higher levels in breast cancer serum compared to serum of healthy volunteers in the discovery cohort. Fourteen of these miRNAs were studied in the validation cohort and serum miR-484 was found to be at a significantly higher level in breast cancer serum compared to healthy volunteers.

Conclusion: In this study, we found that miR-484 is significantly differentially expressed in serum of early breast cancer patients compared to healthy volunteers. We did not however find any correlation between miR-484 levels with histopathological parameters of the breast cancers. With further studies, miR-484 may prove useful as an adjunct to mammography for detection of early breast cancer.

Citing Articles

A machine learning model revealed that exosome small RNAs may participate in the development of breast cancer through the chemokine signaling pathway.

Mo J, Li X, Lei L, Peng J, Liang X, Zhou H BMC Cancer. 2024; 24(1):1435.

PMID: 39574053 PMC: 11580650. DOI: 10.1186/s12885-024-13173-x.

Tumor-derived EV miRNA signatures surpass total EV miRNA in supplementing mammography for precision breast cancer diagnosis.

Kim Y, Kim J, Moon S, Lee H, Lee S, Kim J Theranostics. 2024; 14(17):6587-6604.

PMID: 39479442 PMC: 11519808. DOI: 10.7150/thno.99245.

Liquid biopsy utilizing miRNA in patients with advanced breast cancer treated with cyclin‑dependent kinase 4/6 inhibitors.

Kubeczko M, Tudrej P, Tyszkiewicz T, Krzywon A, Oczko-Wojciechowska M, Jarzab M Oncol Lett. 2024; 27(4):181.

PMID: 38464342 PMC: 10921259. DOI: 10.3892/ol.2024.14314.

Identifying MicroRNAs Suitable for Detection of Breast Cancer: A Systematic Review of Discovery Phases Studies on MicroRNA Expression Profiles.

Padroni L, De Marco L, Fiano V, Milani L, Marmiroli G, Giraudo M Int J Mol Sci. 2023; 24(20).

PMID: 37894794 PMC: 10607026. DOI: 10.3390/ijms242015114.

New insights of miRNA molecular mechanisms in breast cancer brain metastasis and therapeutic targets.

Hussen B, Abdullah K, Abdullah S, Majeed N, Mohamadtahr S, Rasul M Noncoding RNA Res. 2023; 8(4):645-660.

PMID: 37818447 PMC: 10560790. DOI: 10.1016/j.ncrna.2023.09.003.

References

Iorio M, Ferracin M, Liu C, Veronese A, Spizzo R, Sabbioni S . MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005; 65(16):7065-70. DOI: 10.1158/0008-5472.CAN-05-1783. View

Heneghan H, Miller N, Lowery A, Sweeney K, Newell J, Kerin M . Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Ann Surg. 2010; 251(3):499-505. DOI: 10.1097/SLA.0b013e3181cc939f. View

Gilad S, Meiri E, Yogev Y, Benjamin S, Lebanony D, Yerushalmi N . Serum microRNAs are promising novel biomarkers. PLoS One. 2008; 3(9):e3148. PMC: 2519789. DOI: 10.1371/journal.pone.0003148. View

Wang F, Zheng Z, Guo J, Ding X . Correlation and quantitation of microRNA aberrant expression in tissues and sera from patients with breast tumor. Gynecol Oncol. 2010; 119(3):586-93. DOI: 10.1016/j.ygyno.2010.07.021. View

Yan L, Huang X, Shao Q, Huang M, Deng L, Wu Q . MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA. 2008; 14(11):2348-60. PMC: 2578865. DOI: 10.1261/rna.1034808. View

Soon P, Kiaris H . MicroRNAs in the tumour microenvironment: big role for small players. Endocr Relat Cancer. 2013; 20(5):R257-67. DOI: 10.1530/ERC-13-0119. View

Kogure T, Lin W, Yan I, Braconi C, Patel T . Intercellular nanovesicle-mediated microRNA transfer: a mechanism of environmental modulation of hepatocellular cancer cell growth. Hepatology. 2011; 54(4):1237-48. PMC: 3310362. DOI: 10.1002/hep.24504. View

Chen X, Liang H, Zhang J, Zen K, Zhang C . Secreted microRNAs: a new form of intercellular communication. Trends Cell Biol. 2012; 22(3):125-32. DOI: 10.1016/j.tcb.2011.12.001. View

Kong W, Yang H, He L, Zhao J, Coppola D, Dalton W . MicroRNA-155 is regulated by the transforming growth factor beta/Smad pathway and contributes to epithelial cell plasticity by targeting RhoA. Mol Cell Biol. 2008; 28(22):6773-84. PMC: 2573297. DOI: 10.1128/MCB.00941-08. View

10.

Li A, Yu J, Kim H, Wolfgang C, Canto M, Hruban R . MicroRNA array analysis finds elevated serum miR-1290 accurately distinguishes patients with low-stage pancreatic cancer from healthy and disease controls. Clin Cancer Res. 2013; 19(13):3600-10. PMC: 3707520. DOI: 10.1158/1078-0432.CCR-12-3092. View

11.

Roth C, Rack B, Muller V, Janni W, Pantel K, Schwarzenbach H . Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer. Breast Cancer Res. 2010; 12(6):R90. PMC: 3046429. DOI: 10.1186/bcr2766. View

12.

Sand M, Skrygan M, Sand D, Georgas D, Gambichler T, Hahn S . Comparative microarray analysis of microRNA expression profiles in primary cutaneous malignant melanoma, cutaneous malignant melanoma metastases, and benign melanocytic nevi. Cell Tissue Res. 2012; 351(1):85-98. DOI: 10.1007/s00441-012-1514-5. View

13.

Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K . Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008; 18(10):997-1006. DOI: 10.1038/cr.2008.282. View

14.

Papadopoulos G, Alexiou P, Maragkakis M, Reczko M, Hatzigeorgiou A . DIANA-mirPath: Integrating human and mouse microRNAs in pathways. Bioinformatics. 2009; 25(15):1991-3. DOI: 10.1093/bioinformatics/btp299. View

15.

Kozomara A, Griffiths-Jones S . miRBase: integrating microRNA annotation and deep-sequencing data. Nucleic Acids Res. 2010; 39(Database issue):D152-7. PMC: 3013655. DOI: 10.1093/nar/gkq1027. View

16.

Vecchione A, Belletti B, Lovat F, Volinia S, Chiappetta G, Giglio S . A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis. Proc Natl Acad Sci U S A. 2013; 110(24):9845-50. PMC: 3683704. DOI: 10.1073/pnas.1305472110. View

17.

Godfrey A, Xu Z, Weinberg C, Getts R, Wade P, DeRoo L . Serum microRNA expression as an early marker for breast cancer risk in prospectively collected samples from the Sister Study cohort. Breast Cancer Res. 2013; 15(3):R42. PMC: 3706791. DOI: 10.1186/bcr3428. View

18.

Volinia S, Croce C . Prognostic microRNA/mRNA signature from the integrated analysis of patients with invasive breast cancer. Proc Natl Acad Sci U S A. 2013; 110(18):7413-7. PMC: 3645522. DOI: 10.1073/pnas.1304977110. View

19.

Esquela-Kerscher A, Slack F . Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer. 2006; 6(4):259-69. DOI: 10.1038/nrc1840. View

20.

van Schooneveld E, Wouters M, Van der Auwera I, Peeters D, Wildiers H, van Dam P . Expression profiling of cancerous and normal breast tissues identifies microRNAs that are differentially expressed in serum from patients with (metastatic) breast cancer and healthy volunteers. Breast Cancer Res. 2012; 14(1):R34. PMC: 3496152. DOI: 10.1186/bcr3127. View